William Blair


Gilead Sciences, Inc. (GILD) Has Solid Catalysts for Continued Growth; William Blair Sets Fair Value at $87

Kite acquisition signals Gilead’s leadership and continued consolidation moving forward, says Katherine Xu

What’s Next for QUALCOMM, Inc.’s (QCOM) Licensing Business? William Blair Weighs In

Skepticism Circles Qualcomm’s Licensing Business Following President’s Departure

Abercrombie & Fitch Co. (ANF) 2Q17 Beat Shows Encouraging Momentum: William Blair

Analyst Sees Long-Term Benefits for A&F and Hollister Thanks to New Loyalty Program Launches

Ulta Beauty Inc (ULTA) Well-Positioned Heading into Q2 Print: William Blair

Ulta Beauty Inc (NASDAQ:ULTA) will release second quarter results on Thursday, August 24th and analyst Daniel Hofkin of William Blair is out with a …

Endo International plc – Ordinary Shares (ENDP) Near-Term Challenges Offset 2Q Earnings Beat

Despite Endo International plc – Ordinary Shares (NASDAQ:ENDP) delivering a second-quarter earnings beat on Tuesday, with the management team forced to pull back …

William Blair Boosts Price Target for Dynavax Technologies Corporation (DVAX) as VRBPAC Panel Gives Thumbs Up to Heplisav

William Blair analyst Y Katherine Xu is out with a bullish note on shares of Dynavax Technologies Corporation (NASDAQ:DVAX), after the FDA’s Vaccines and Related Biological …

William Blair Bullish on Biotech: Sarepta Therapeutics Inc (SRPT), Dynavax Technologies Corporation (DVAX), and Exelixis, Inc. (EXEL)

Sarepta’s $12+ Million 2Q Beat Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech …